Navigation Links
Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia
Date:3/10/2009

Former AstraZeneca Exec to Lead Hong Kong-based subsidiary Pangu BioPharma

SAN DIEGO, March 10 /PRNewswire/ -- aTyr Pharma, a privately held biopharmaceutical company focused on discovery and development of an entirely new class of natural protein therapeutics (biologics) for multiple disease indications, today announced that Dr. James Cai has joined the Company as Senior Vice President of Clinical Development at aTyr Pharma and President of Pangu BioPharma, a fully owned aTyr Pharma subsidiary in Hong Kong.

With over a decade of experience developing and leading research and development in Asia for leading pharmaceutical companies, Dr. Cai's industry and regional expertise will position both aTyr Pharma and Pangu BioPharma to fully take advantage of the unique growth opportunities of Asia. Most recently, Dr. Cai was Vice President of Research and Development at AstraZeneca China. In this role he established the Research and Development organization in China and was responsible for Clinical Research, Medical-Marketing, Regulatory Affairs, Patient Safety and Business Development. During his tenure, the team launched Iressa and Crestor, with $265 M and $3.6 B in global annual sales respectively

"We are thrilled to have Dr. James Cai join aTyr Pharma and Pangu BioPharma as a key member of our management team," said Dr. Jeff Watkins, CEO of aTyr Pharma. "His many years of hands on clinical development, paired with deep relationships in Asia and a proven ability to drive drug discovery forward in the region make Dr. Cai perfectly suited for his role as the leader of our subsidiary Pangu BioPharma."

Prior to joining AstraZeneca, Dr. Cai was External Affairs and HIV Franchise Director at Merck Sharp & Dohme China and Medical Director at Pfizer. Dr. Cai graduated from Columbia University with Executive MBA, and trained as physician and clinical researcher from Shanghai Second Me
'/>"/>

SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
2. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
3. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
4. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
5. ARCA biopharma Appoints James Carr as Vice President of Marketing
6. James C. Powell Joins Nerites Board of Directors
7. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
8. Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
9. James T. Glover Appointed to Board of Directors of Varian, Inc.
10. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... BioTrends Research Group, one of the ... biopharmaceutical issues, finds that, unaided, one in five ... that in the past six months, they have ... anticipation of the next generation of HCV treatments—notably ... 6 percent reported that they had begun warehousing ...
(Date:5/23/2013)... -- Z Trim Holdings, Inc. (OTC Markets: ZTHO), a ... industries, announced that Chef Erin Ryan ... National Restaurant Association ("NRA") NRA Show, which was held ... Chefs Association.  Chef Ryan spoke on the subject of ... the Ugly," joining four other prestigious panelists including:  Kit ...
(Date:5/23/2013)... 23, 2013 The New Jersey chapter ... Black Data Processing Associates (BDPA), is hosting its 10th ... 2013. This all-day event will encourage students and their ... ins and outs from many of the industries’ finest ... the New Jersey Institute of Technology, the event will ...
(Date:5/23/2013)... , May 23, 2013  Verenium Corporation (Nasdaq: ... on the development and commercialization of high-performance enzymes, today ... Financial Officer, will present at two upcoming conferences. ... will present at the Second Annual Marcum LLP Microcap ... Hyatt Hotel in New York City.  The presentation is ...
Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... SAN DIEGO, Feb. 15, 2011 Ceregene, ... and collaborators have published new experimental findings in support ... lead article in the current issue of Movement Disorders ... publication reports the first evidence that gene transfer can ...
... has just launched the first European repository of ... types of reference nanomaterials. This will support safety ... many innovative applications and products. Nanotechnology is one ... a harmonised risk assessment the repository can contribute ...
... RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2011 ... 59th annual Neurological Society of India & Congress ... this past December.  The event was a convergence ... and researchers from across the globe to discuss ...
Cached Biology Technology:Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 2Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 3Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 4Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 5Small material, big impact 2Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India 2
(Date:5/24/2013)... and other non-coding RNAs are small molecules that ... recent years they have emerged as disease biomarkers. ... origin for cancers of unknown primary origin, determine ... but clinically tractable, diagnostic methods for monitoring miRNA ... In this issue of the Journal of ...
(Date:5/24/2013)... 500 leading water scientists from around the world today ... the short span of one or two generations, the ... be living under the handicap of severe pressure on ... there is no substitute. This handicap will be self-inflicted ... bluntly pointed to chronic underlying problems led by mismanagement ...
(Date:5/23/2013)... National Laboratory honored more than 165 staff for ... at PNNL,s annual Intellectual Property Commercialization Recognition & ... Energy national laboratory named materials scientist Jun Liu ... battery materials that can store large amounts of ... reduce the time it takes to charge cell ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... have developed a commercially viable method for mass producing ... instead of the months required for traditional egg-based vaccines. ... Biodefense Research , The next flu pandemic could happen ... Sciences Corporation (PSC) and a researcher on the study. ...
... to someone talk and also hearing the buzz of the ... conversation down the hallway. To focus on the person speaking ... all incoming sensory information. It has to attend to what ... the Stanford University School of Medicine have taken a big ...
... Allergy and Infectious Diseases (NIAID), part of the ... enrollment into a large international HIV/AIDS trial comparing ... by levels of CD4+ cells has been stopped. ... therapy had twice the risk of disease progression ...
Cached Biology News:New influenza vaccine takes weeks to mass produce 2Stanford study of owls finds link in brain between sight and sound 2Stanford study of owls finds link in brain between sight and sound 3International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 2International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 3International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 4
These stopping screens are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 screens....
... GEMINI is Tecan's pipetting software for ... GENESIS Freedom and the GENESIS WORKSTATION instruments ... intuitive software enables the user the simple ... of pipetting scripts. With the powerful scripting ...
...
Biotin or fluorescent labels can be attached and the stoichiometry of protein labeling determined....
Biology Products: